CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Glucocorticoid-related changes in body mass index among children and adolescents with rheumatic diseases
Authors
Nathalie Alos
Stephanie A. Atkinson
+26 more
Rollin Brant
David A Cabral
Jean Paul Collet
Robert Couch
Elizabeth A. Cummings
Peter B. Dent
Janet Ellsworth
Jaime Guzman
John Hay
Kristin Houghton
Adam M. Huber
Roman Jurencak
Bianca Lang
Maggie Larche
Claire LeBlanc
Paivi M. Miettunen
Frank Rauch
Celia Rodd
Johannes Roth
Claire Saint-Cyr
Rosie Scuccimarri
Natalie J Shiff
Robert Stein
David Stephure
Shayne Taback
Leanne M. Ward
Publication date
1 January 2013
Publisher
Scholarship@Western
Doi
Cite
View
on
PubMed
Abstract
Objective To examine the temporal and dose-related effects of glucocorticoids (GCs) on body mass index (BMI) in children with rheumatic diseases. Methods Children initiating GCs for a rheumatic disease (n = 130) were assessed every 3 months for 18 months. BMI, weight, and height Z score trajectories were described according to GC starting dosage in prednisone equivalents: high (≥1.0 mg/kg/day), low (\u3c0.2 mg/kg/day to a maximum of 7.5 mg/day), and moderate (between high and low) dosage. The impact of GC dosing, underlying diagnosis, pubertal status, physical activity, and disease activity on BMI Z scores and on percent body fat was assessed with longitudinal mixed-effects growth curve models. Results The GC starting dose was high in 59% and moderate in 39% of patients. The peak BMI Z score was +1.29 at 4 months with high-dose GCs and +0.69 at 4.2 months with moderate-dose GCs (P \u3c 0.001). Overall, 50% (95% confidence interval 41-59%) of the children returned to within +0.25 SD of their baseline BMI Z score. Oral GC dose over the preceding 3 months was the most significant determinant of BMI Z score and percent body fat. The proportion of days in receipt of GCs, disease activity, and a diagnosis of systemic-onset juvenile idiopathic arthritis were also associated with BMI Z scores. The correlation between changes in BMI and changes in percent body fat was 0.09. Conclusion In children with rheumatic diseases starting moderate and high doses of GCs, BMI Z scores peaked at 4 months, and only half returned to within +0.25 SD of their baseline BMI Z score after 18 months. Copyright © 2013 by the American College of Rheumatology
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Scholarship@Western
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:ir.lib.uwo.ca:paedpub-2979
Last time updated on 08/10/2022